Evidence Table G2. CONTINUOUS outcomes for class RETINOID (TOPICAL))/ANTI-BACTERIAL (TOPICAL).

Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

G.02.01 Tretinoin + clindamycin Clindamycin

46 Severity (cook) Short (4) Measure: 4 Measure: 3

Parallel Mod/sev

N=40

45 N=209 Severity (cook) Short (4) Measure: 4 Measure: 3 NS

47 N=162 Severity (cook) Short (4) Measure: 4 Measure: 4

283 Dryness (severity) Short (6) Measure: 1 Measure: 0

Parallel Mild/mod/sev

N=64

Erythema (severity) Short (6) Measure: 1 Measure: 0 NS

Comedones change (%)

Count location: Unspecified. Between Pvalue: T + C vs C: significant.

Mid (8) Percent change: -48 Percent change: -20 "Signifi

cant"

Dryness (severity) Mid (8) Measure: 2 Measure: 0 NS

Erythema (severity) Mid (8) Measure: 1 Measure: 0 NS

Papules change (%)

Count location: Unspecified. 

Mid (8) Percent change: -52 Percent change: -53 NS

Pustules change (%) Mid (8) Percent change: -60 Percent change: -62 NS

Severity (cook) Mid (8) Measure: 4 Measure: 3 NS

47 Inflammatory change (%) Mid (12) Percent change: -64 Percent change: -57

Parallel Mod/sev

N=162 NS

46 N=40 Inflammatory change (%) Mid (12) Percent change: -89 Percent change: -71 NS

45 N=209 Inflammatory change (%) Mid (12) Percent change: -76 Percent change: -58 NS

47 N=162 Non-inflammatory change (%) Mid (12) Percent change: -64 Percent change: -51 0.04

46 N=40 Non-inflammatory change (%) Mid (12) Percent change: -69 Percent change: -43 NS

45 N=209 Non-inflammatory change (%) Mid (12) Percent change: -69 Percent change: -61 0.05

Severity (cook) Mid (12) Measure: 2 Measure: 2 0.007

47 N=162 Severity (cook) Mid (12) Measure: 2 Measure: 2 0.001

46 N=40 Severity (cook) Mid (12) Measure: 2 Measure: 2 NS

G.02.02 Tretinoin + Clindamycin Tretinoin

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable G CONTINUOUS: Page 1 of 2

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

42 Severity (cook) Short (4) Measure: 3 Measure: 3

Parallel Mod/sev

N=40 NS

43 N=161 Severity (cook) Short (4) Measure: 4 Measure: 4 NS

44 N=157 Severity (cook) Short (4) Measure: 4 Measure: 4 NS

43 Inflammatory change (%)

Count location: Unspecified. 

N=161 Mid (12) Percent change: -72 Percent change: -55 0.001

42 N=40 Inflammatory change (%) Mid (12) Percent change: -81 Percent change: -53 0.04

44 N=157 Inflammatory change (%) Mid (12) Percent change: -62 Percent change: -48 NS

42 N=40 Non-inflammatory change (%) Mid (12) Percent change: -75 Percent change: -64 NS

44 N=157 Non-inflammatory change (%) Mid (12) Percent change: -68 Percent change: -65 NS

43 N=161 Non-inflammatory change (%) Mid (12) Percent change: -59 Percent change: -53 NS

42 N=40 Severity (cook) Mid (12) Measure: 1 Measure: 2

43 N=161 Severity (cook) Mid (12) Measure: 2 Measure: 3 0.009

44 N=157 Severity (Cook) Mid (12) Measure: 2 Measure: 2 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable G CONTINUOUS: Page 2 of 2

ÈÍ